Use of 1alpha-OH cholecalciferol in preventing post parturient hypocalcaemia and its potential value for the prevention of milk fever in dairy cows

Cows which received 250 mug 1alpha-hydroxy cholecalciferol (1alpha-OH D3) intramuscularly within two hours after calving suffered significantly less post-parturinet hypocalcaemia and hypophosphataemia than control cows. There was a small depression in plasma magnesium concentrations in the treated cows. 1alpha-OH D3 shows potential for the prevention or treatment of milk fever.     

Stress-induced gonadotropin and prolactin secretory patterns

To further evaluate the influence that sex, time of day and/or stage of the estrous cycle have on stress-induced changes in gonadotropin secretory patterns, rats were subjected to acute ether stress and subsequently sacrificed at 1.5, 3, 5, 10 and 15-min intervals. A significant change in FSH levels was not detectable, however serum LH levels consistently showed a transient elevation, and prolactin release occurred rapidly and in large increments in every case. Variation in basal hormone levels due to sex, circadian rhythmicity, or estrous cyclicity did not alter the pattern of the response of individual hormones to the stress but did markedly influence the magnitude of the response.     

An interactional approach to dysfunctional silencing in family therapy

This paper presents an interactional approach to the problem of dysfunctional silencing in family therapy. Silencing is classified as dysfunctional if it satisfies two conditions: (a) it occurs repeatedly and independently of content, and (b) it functions as negative feedback that limits change in the family system. Dysfunctional silencing is defined as those efforts of one or more family members to limit change by repeatedly blocking the communication of another family member, who in turn colludes by tacitly agreeing to remain silent. The interactional approach presented utilizes conflict-resolution techniques and videotape feedback; it is illustrated by a case example.     

Ventilation, gas exchange and metabolic scaling of a sea turtle

A new dichromic interference filter was used as the excitation filter in colour and black-and-white fluorescein angiography of the human fundus. The interference filter transmits light shorter than 490 nm (blue) and longer than 640 nm (red). In colour photography the red light shows the topography of the fundus. In black-and-white photography, the red light is prevented from reaching the fundus by an additional absorption filter used together with the interference filter. These two comprise the excitation filter, which eliminates the pseudo-fluorescence from black-and-white angiograms.     

Dietary calcium decreases blood pressure without decreasing renal vascular resistance or altering the response to NO blockade

Many vasoactive elements are involved in the elevation of blood pressure in spontaneously hypertensive rats (SHR). Elevated dietary calcium has been observed to reduce blood pressure in SHR. This study investigates interactions among dietary calcium, renal vascular resistance (RVR), elevation of blood pressure and effects of norepinephrine and nitric oxide synthesis. We completed a series of experiments on two groups each (fed low, 0.1% and high, 2.0% dietary calcium, respectively) of 9-week-old Wistar Kyoto (WKY), 9-week-old and 6-week-old SHR. Although 9-week-old SHR had elevated baseline blood pressure compared to 9-week-old WKY and also compared to 6 week-old SHR, there was no corresponding elevation in baseline RVR. All SHR fed high calcium diets had lower blood pressure compared to low calcium diets, and there was no corresponding reduction in RVR. WKY controls' blood pressure and RVR were unaffected by dietary calcium levels. In all hypertensive rats the blood pressure and renal vascular resistance were elevated by N(G)-nitro-L-arginine methylester (L-NAME), but the dietary differences were sustained. Blood pressure of WKY was unaffected by the low dose of L-NAME. The increase in RVR to L-NAME was greater in SHR than in controls. The renal vascular response to norepinephrine was related to diet in older SHR, but smaller and unrelated to diet in younger SHR. Following L-NAME, WKY had greater responses to norepinephrine than 9-week-old SHR. We conclude that noradrenergic vasoconstriction is enhanced in the adult SHR, especially in the absence of high calcium diet. Alterations in NO synthesis may effect the norepinephrine response.     

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

CONTEXT: Orlistat, a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, may promote weight loss and reduce cardiovascular risk factors. OBJECTIVE: To test the hypothesis that orlistat combined with dietary intervention is more effective than placebo plus diet for weight loss and maintenance over 2 years. DESIGN: Randomized, double-blind, placebo-controlled study conducted from October 1992 to October 1995. SETTING AND PARTICIPANTS: Obese adults (body mass index [weight in kilograms divided by the square of height in meters], 30-43 kg/m2) evaluated at 18 US research centers. INTERVENTION: Subjects received placebo plus a controlled-energy diet during a 4-week lead-in. On study day 1, the diet was continued and subjects were randomized to receive placebo 3 times a day or orlistat, 120 mg 3 times a day, for 52 weeks. After 52 weeks, subjects began a weight-maintenance diet, and the placebo group (n = 133) continued to receive placebo and orlistat-treated subjects were rerandomized to receive placebo 3 times a day (n = 138), orlistat, 60 mg (n = 152) or 120 mg (n = 153) 3 times a day, for an additional 52 weeks. MAIN OUTCOME MEASURES: Body weight change and changes in blood pressure and serum lipid, glucose, and insulin levels. RESULTS: A total of 1187 subjects entered the protocol, and 892 were randomly assigned on day 1 to double-blind treatment. For intent-to-treat analysis, 223 placebo-treated subjects and 657 orlistat-treated subjects were evaluated. During the first year orlistat-treated subjects lost more weight (mean +/- SEM, 8.76+/-0.37 kg) than placebo-treated subjects (5.81+/-0.67 kg) (P<.001). Subjects treated with orlistat, 120 mg 3 times a day, during year 1 and year 2 regained less weight during year 2 (3.2+/-0.45 kg; 35.2% regain) than those who received orlistat, 60 mg (4.26+/-0.57 kg; 51.3% regain), or placebo (5.63+/-0.42 kg; 63.4% regain) in year 2 (P<.001). Treatment with orlistat, 120 mg 3 times a day, was associated with improvements in fasting low-density lipoprotein cholesterol and insulin levels. CONCLUSIONS: Two-year treatment with orlistat plus diet significantly promotes weight loss, lessens weight regain, and improves some obesity-related disease risk factors.     

In vitro lipid peroxidation of LDL from postmenopausal cynomolgus macaques treated with female hormones

We constructed a sensitive and quantitative assay system to examine human T-cell leukemia virus type I (HTLV-I) envelope (env) glycoprotein-mediated cell fusion in which T7 RNA polymerase in donor cells coexpressing env glycoproteins activates a reporter gene in recipient cells upon cell fusion. An efficient expression of HTLV-I env glycoproteins (gp46 and gp21) was observed in 293T cells transfected with an expression plasmid by both immunoblot and immunofluorescence analyses. The cells expressing env glycoproteins also exhibited self-fusion. By cocultivating the donor cells with recipient cells transfected with a reporter plasmid possessing the luciferase gene under the T7 promoter, the expression of luciferase was observed upon cell fusion. The activation of the luciferase gene was inhibited by either anti-env neutralizing antibody or synthetic peptide corresponding to env gp21, thus indicating the cell fusion to be specifically mediated by the HTLV-I env glycoproteins expressed in the donor cells. A broad range of cell lines exhibited susceptibility to HTLV-I env-mediated cell fusion by this assay. This newly established assay system may thus provide an efficient way both to study the fusion mechanisms mediated by HTLV-I env glycoproteins and to identify the HTLV-I receptor(s).